combination therapy, immunotherapy, metastatic melanoma, oncolytic virus, real-world evidence, talimogene laherparepvec, T-VEC
Aim: Talimogene laherparepvec (T-VEC) is an intralesional therapy for unresectable, metastatic melanoma. T-VEC real-world use in the context of anti-PD1-based therapy requires further characterization.
Materials & methods: A retrospective review of T-VEC use from 1 January 2017 and 31 March 2018 for melanoma patients was conducted at seven US institutions.
Results: Among 83 patients, three categories of T-VEC and anti-PD-1 therapy were identified: T-VEC used without anti-PD-1 (n = 29, 35%), T-VEC after anti-PD-1-based therapy (n = 22, 27%) and concurrent T-VEC and anti-PD-1-based therapy (n = 32, 39%). 25% of patients discontinued T-VEC therapy due to no remaining injectable lesions, 37% discontinued T-VEC due to progressive disease. Discontinuation of T-VEC did not differ by anti-PD-1-based therapy use or timing.
Conclusion: In real-world settings, T-VEC may be used concurrently with or after anti-PD-1-based therapy.
Digital Object Identifier (DOI)
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Citation / Publisher Attribution
Melanoma Management, v. 7, issue 2, art. 0005
Scholar Commons Citation
Sun, James; Gastman, Brian R.; McCahon, Lucy; Buchbinder, Elizabeth I.; Puzanov, Igor; Nanni, Michele; Lewis, James M.; Carvajal, Richard D.; Singh-Kandah, Shahnaz; Desai, Anupam M.; Raskin, Leon; Nielson, Carrie M.; Ismail, Rubina; and Zager, Jonathan S., "Observational Study of Talimogene Laherparepvec Use in the Anti-pd-1 Era for Melanoma in the US (Cosmus-2)" (2020). Oncologic Sciences Faculty Publications. 9.
Was this content written or created while at USF?